SBIR Phase I: Design And Production Of IgG Fc Carrier Scaffolds With Increased Payload Capacity

这个小型企业创新研究(SBIR)第一阶段项目将开始解决目前在多肽药物输送和化学蛋白质结合方面的一些挑战。使用红木生物科学公司的专利技术平台--蛋白质工程技术，可以将含有独特手柄的非标准氨基酸插入到任何感兴趣的蛋白质中。例如，这种独特的手柄，一个“醛标签”，可以用合成的治疗性多肽进行特殊的化学阐述。在红木生物科学公司，这项蛋白质工程技术被用来产生通用的蛋白质支架，即免疫球蛋白Fc结构域，这种结构域易于化学阐述，可产生均一产品，并可用作长效蛋白质-多肽疗法。重要的是，利用这项技术，有可能精心制作具有多个标签的蛋白质支架，用于小分子的结合，增加载体支架的潜在有效载荷能力。这项研究的更广泛/商业影响是开发具有更高有效载荷能力的同类最佳疗法，并由此提供足够高浓度的所需药物。与现有技术相比，这是一个重大而实质性的改进。此外，通过扩大蛋白质药物的化学空间，红杉S技术已应用于开发具有独特蛋白质化学结构的新型杂化药物，包括具有增强有效载荷能力的多价结构。该公司计划扩大其同类最佳治疗化合物的流水线，将Fc支架载体蛋白装载到多肽或小分子候选分子中，这些候选多肽或小分子被确定为潜在的治疗药物，目前正遭受着糟糕的PK图谱。

This Small Business Innovation Research (SBIR) Phase I project will begin to address some of the current challenges in peptide drug delivery and chemical protein conjugation. Using Redwood Bioscience's patented technology platform, a protein engineering technique, it is possible to insert a non-canonical amino acid containing a unique handle into any protein of interest. This unique handle, an "aldehyde tag", can be specifically elaborated chemically with a synthetic therapeutic peptide, for example. At Redwood Bioscience, this protein engineering technology is used to generate universal protein scaffolds, IgG Fc domains, that are easy to chemically elaborate, result in a homogenous product and can be used as long lasting protein-peptide therapies. Importantly, using this technology it is possible to elaborate the protein scaffolds with multiple tags for small molecule attachment, increasing the potential payload capacity of the carrier scaffold.The broader/commercial impact of this research is the development of best in class therapeutics with increased payload capacity and the resulting delivery of sufficiently high concentrations of a desired drug. This is a significant and substantial improvement over the current technologies available. Moreover, through ?expanding the chemical space of protein drugs?, Redwood?s technology has application in developing novel hybrid drugs with unique protein-chemical architectures, including multivalent constructs with enhanced payload capacity. The company plans to expand its pipeline of best in class therapeutic compounds, loading Fc scaffold carrier proteins with peptide or small molecule candidates, identified as potential therapeutics currently suffering from poor PK profiles.